Gender differences regarding novel biomarkers and metabolic risk factors in metformin treated type 2 diabetic patients

Open Diabetes Journal

Volumn 5, Issue 1, 2012, Pages 13-19

  Wändell, Per E ^a   Gigante, Bruna ^a   Andreasson, Anna Nixon ^a,b   Carlsson, Axel C ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Adiponectin; Diabetes; Factor analysis; Ghrelin; Insulin resistance; Leptin

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GHRELIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

EID: 84861880478     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601205010013     Document Type: Article

References (36)

1. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004; 27: 889-94.
2. Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-75.
3. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012; 165: 574-90.
4. Hasan-Ali H, Abd El-Mottaleb NA, Hamed HB, Abd-Elsayed A. Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. Coron Artery Dis 2011; 22: 264-9.
5. Delhanty PJ, van der Lely AJ. Ghrelin and glucose homeostasis. Peptides 2011; 32: 2309-18.
6. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009; 53: 167-75.
7. Carlsson AC, Nixon Andreasson A, Wandell PE. Poor self-rated health is not associated with a high total allostatic load in type 2 diabetic patients--but high blood pressure is. Diabetes Metab 2011; 37: 446-51.
8. Wandell PE, Carlsson AC, Andersson K, Gafvels C, Tornkvist L. Tactile massage or relaxation exercises do not improve the metabolic control of type 2 diabetics. Open Diabetes J 2010; 3: 6-10.
9. Wandell PE, Carlsson A, Steiner KH. Prevalence of diabetes among immigrants in the Nordic countries. Curr Diabetes Rev 2010; 6: 126-33.
10. Carlsson AC, Wandell PE, de Faire U, Hellenius ML. Prevalence of hypertension in immigrants and Swedish-born individuals, a crosssectional study of 60-year-old men and women in Sweden. J Hypertens 2008; 26: 2295-302.
11. Andersson K, Tornkvist L, Wandell P. Tactile massage within the primary health care setting. Complement Ther Clin Pract 2009; 15: 158-60.
12. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
13. Nakatochi M, Miyata S, Tanimura D, et al. The ratio of adiponectin to homeostasis model assessment of insulin resistance is a powerful index of each component of metabolic syndrome in an aged Japanese population: results from the KING Study. Diabetes Res Clin Pract 2011; 92: e61-5.
14. Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 2005; 54: 281-6.
15. Wandell PE, Carlsson AC, Theobald H. The association between BMI value and long-term mortality. Int J Obes (Lond) 2009; 33: 577-82.
16. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-61.
17. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100.
18. Kuo SM, Halpern MM. Lack of association between body mass index and plasma adiponectin levels in healthy adults. Int J Obes (Lond) 2011; 35: 1487-94.
19. Saad MF, Damani S, Gingerich RL, et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579-84.
20. Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996; 81: 3424-7.
21. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001; 44: 3-15.
22. Wandell PE, Gafvels C. Patients with type 2 diabetes aged 35-64 years at four primary health care centres in Stockholm County, Sweden. Prevalence and complications in relation to gender and socio-economic status. Diabetes Res Clin Pract 2004; 63: 195-203.
23. McNeely MJ, Boyko EJ, Weigle DS, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care 1999; 22: 65-70.
24. Soderberg S, Zimmet P, Tuomilehto J, et al. Leptin predicts the development of diabetes in Mauritian men, but not women: a population-based study. Int J Obes (Lond) 2007; 31: 1126-33.
25. Franks PW, Brage S, Luan J, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13: 1476-84.
26. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 2003; 163: 1735-40.
27. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002; 162: 1737-45.
28. de Fine Olivarius N, Siersma V, Nielsen AB, Hansen LJ, Rosenvinge L, Mogensen CE. Predictors of mortality of patients newly diagnosed with clinical type 2 diabetes: a 5-year follow up study. BMC Endocr Disord 2010; 10: 14.
29. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88: 4823-31.
30. Turer AT, Khera A, Ayers CR, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011; 54: 2515-24.
31. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-200.
32. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.
33. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-5.
34. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011; 93: 56-62.
35. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123: 551-65.
36. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-7.